ReviewInternal medicine (Tokyo, Japan)2026
Standard and Non-standard Cardiovascular Risk Factors in Ischemic Heart Disease and Atherosclerotic Cardiovascular Disease: A Clinical Review.
Review in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Incremental Impact of Standard Modifiable Cardiovascular Risk Factors on Long-Term Outcomes After Acute Myocardial Infarction.JACC. Asia · 2026Article
- Diagnostic, Prognostic and Therapeutic Utility of MicroRNA-21 in Ischemic Heart Disease.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic cardiovascular diseases, including ischemic heart disease (IHD), remain the leading cause of morbidity and mortality worldwide and are typically induced by the detrimental effects of risk factors on the cardiovascular system. Although some risk factors, such as age and sex, are non-modifiable, the identification and therapeutic interventions against standard modifiable cardiovascular risk factors (SMuRFs), namely hypertension, dyslipidemia, diabetes, smoking, and obesity, contribute to improved cardiovascular outcomes. Beyond SMuRFs, non-traditional, potentially modifiable risk factors for IHD have been identified, such as inflammation, lipoprotein(a), and air pollution. This review article summarizes recent clinical evidence regarding SMuRFs and non-traditional risk factors for IHD and atherosclerotic cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.